---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-21-000127"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2021-11-23T23:59:59+00:00"
generated_at: "2026-06-28T05:49:00.223263+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunovant enters $36M manufacturing deal with Samsung Biologics for batoclimab

## Summary
- Minimum purchase commitment estimated at $36M; PSA runs through Dec 31, 2029.
- Immunovant can terminate if it stops all batoclimab development by Jan 2024, paying non-cancellable fees.
- Samsung will manufacture batoclimab drug substance for commercial sale, including process performance qualification batches.
- Agreement builds on Master Services Agreement dated April 30, 2021.
- Either party may terminate for material breach, insolvency, or force majeure.

## SEC filing metadata
- accession: 0001764013-21-000127
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2021-11-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000127/0001764013-21-000127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000127/imvt-20211117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-21-000127
- JSON: https://secwatch.observer/filing/0001764013-21-000127.json
- Plain text: https://secwatch.observer/filing/0001764013-21-000127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.